Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease
Author:
Affiliation:
1. Department of Veterans Affairs, Population Health Services; Palo Alto Health Care System; Palo Alto CA
Publisher
Wiley
Subject
Hepatology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/hep.29811/fullpdf
Reference39 articles.
1. Reversion of disease manifestations after HCV eradication;Meer;J Hepatol,2016
2. Management of the patient with SVR;Terrault;J Hepatol,2016
3. Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the Veterans Affairs national healthcare system;Ioannou;Gastroenterology,2016
4. Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice;Backus;Aliment Pharmacol Ther,2016
5. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection;Afdhal;N Engl J Med,2014
Cited by 138 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Financial incentives to motivate treatment for hepatitis C with direct acting antivirals among Australian adults (The Methodical evaluation and Optimisation of Targeted IncentiVes for Accessing Treatment of Early-stage hepatitis C: MOTIVATE-C): protocol for a dose-response randomised controlled study;Trials;2024-06-17
2. Hepatocellular carcinoma after direct‐acting antivirals for hepatitis C is associated with KIR‐HLA types predicting weak NK cell‐mediated immunity;European Journal of Immunology;2024-05-03
3. Optimal hepatitis C treatment adherence patterns and sustained virologic response among people who inject drugs: The HERO study;Journal of Hepatology;2024-05
4. Non‐liver‐related mortality in the DAA era: Insights from post‐SVR patients with and without previous HCC history;Journal of Medical Virology;2024-03
5. Comparing the Risk of Poor Outcomes Among Hepatitis C–Infected, Cured, and Never-Infected Controls;Gastro Hep Advances;2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3